Real-world treatment patterns in patients with generalized pustular psoriasis (GPP).

Background: Generalized pustular psoriasis (GPP) is a chronic and life-threatening inflammatory skin disease, distinct from plaque psoriasis (PsO). There is a lack of GPP treatment guidelines.

Objective: To characterize treatment patterns among patients with GPP in the US during two 365-day periods (post-diagnosis and pre-diagnosis) between 2015 and 2020.

SPECTREM Phase 3b Clinical Trial Results Through Week 16: Guselkumab Efficacy and Safety for the Treatment of Low Body Surface Area, Moderate Psoriasis With High-Impact Site Involvement.

Background: Patients with psoriasis affecting a low percentage of their body surface area (BSA) are underrepresented in clinical studies and may face substantial disease burden if high-impact sites are affected.

Objectives: SPECTREM is a Phase 3b, randomized, placebo-controlled study evaluating guselkumab efficacy and safety in participants with low BSA (2%-15%), moderate (Investigator's Global Assessment [IGA]=3) plaque psoriasis involving ≥1 high-impact site (scalp, face, genitals, intertriginous areas).

Methods: Eligible participants were randomized 2:1 to receive guselkumab 100 mg or placebo at Week 0 and Week 4, then every 8 weeks.

Secukinumab in the Treatment of Moderate-to-Severe Hidradenitis Suppurativa: Pooled Pharmacokinetics and Safety Results From the SUNSHINE and SUNRISE Phase 3 Studies.

Background: Secukinumab, a fully human, monoclonal antibody targeting interleukin-17A, is approved for moderate-to-severe HS in adults. This study evaluated pharmacokinetics (PK), high-sensitivity C-reactive protein (hsCRP) changes, and safety of secukinumab over 52 weeks in SUNSHINE and SUNRISE Phase 3 trials.

Methods: An exploratory analysis of pooled Phase-3 trials evaluated serum PK and safety of secukinumab 300 mg every 2 (SECQ2W) or 4 weeks (SECQ4W).

Comparative Risk of Infection and Prevalence of Combination Targeted Therapy in Psoriatic Arthritis.

Importance: Achieving good disease control in psoriatic arthritis (PsA) remains a major challenge. Combining multiple systemic immunomodulatory therapies has been shown to be beneficial in other immune-mediated diseases with reasonable safety profiles, but data on the current use and safety of combination targeted therapy among individuals with PsA are limited.

Objective: To evaluate the use and safety of combination targeted therapies among adults with PsA.

A Global Assessment of Patient Experience and Quality of Life in Generalized Pustular Psoriasis: Results from Interviews and Online Surveys.

Introduction: Generalized pustular psoriasis (GPP) is a chronic, systemic, neutrophilic inflammatory disease that significantly impacts patients' quality of life (QoL). A multinational panel of patients with GPP participated in surveys and interviews, with the aim to assess the impact of chronic symptoms and GPP flares on QoL and well-being, and to better understand the resources and support that patients need.

Methods: Patients (aged 18-65 years) with a confirmed diagnosis of GPP (> 1 month), who had experienced ≥ 1 flare in the past year and were receiving active treatment for GPP were recruited through databases and healthcare professionals (HCPs).

Streamlining Psoriatic Arthritis Screening and Management Using the IDEOM Clinical Framework: A Quality Improvement Initiative.

Background: Psoriatic arthritis (PsA) is undiagnosed in up to 41% of cases, risking irreversible joint damage if untreated. This quality improvement initiative facilitates PsA screening, assessment, and rheumatology referral to improve patient outcomes.

Methods: Our clinical framework integrated the Psoriasis Epidemiology Screening Tool (PEST) and the 12-item Psoriatic Arthritis Impact of Disease questionnaire (PsAID-12) into the electronic medical record system in 26 dermatology clinics.

Report of the IDEOM Meeting Adjacent to the GRAPPA 2024 Annual Meeting.

The International Dermatology Outcome Measures (IDEOM) organization presented updates on its patient-reported outcome measures (PROMs) for psoriasis (PsO), psoriatic arthritis (PsA), and other immune-mediated skin diseases at the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2024 annual meeting. The Hidradenitis Suppurativa working group reported on the IDEOM Musculoskeletal Questionnaire (MSK-Q), a PROM for MSK manifestations of psoriatic disease. Advances in PsA screening included integrating the Psoriasis Epidemiology Screening Tool (PEST) and 12-item Psoriatic Arthritis Impact of Disease (PsAID-12) questionnaires into the Epic electronic health record system to streamline detection and management of emerging PsA cases.

Ixekizumab and Malignant Neoplasms: A Pooled Analysis of Data From 25 Randomized Clinical Trials.

Importance: Assessing malignant neoplasm risk among patients with long-term biologic exposure is of interest. This study provides insight into the risk of malignant neoplasm among patients with psoriasis (PsO), psoriatic arthritis (PsA), or axial spondyloarthritis (axSpA) who received ixekizumab (IXE) over time.

Objective: To determine the incidence of malignant neoplasms among patients with PsO, PsA, or axSpA who received long-term (up to 6 years) IXE treatment, and to compare the recorded incidences (excluding nonmelanoma skin cancer) with those observed in the US general population.

Pyoderma Gangrenosum in Pregnancy: A Systematic Review of Clinical Characteristics, Treatment Outcomes, and Maternofetal Implications.

Background: Although cases of pyoderma gangrenosum (PG) during pregnancy have been reported, comprehensive data are limited. This review aims to (1) analyze the demographic and clinical characteristics of PG in pregnant and postpartum patients, (2) assess the frequency and effectiveness of treatments, and (3) explore the maternal and fetal implications of PG.

Methods: A systematic review was conducted following PRISMA guidelines, with searches in PubMed, Embase, and Web of Science up to September 27, 2023.

All-Cause Mortality is Higher in Generalized Pustular Psoriasis (GPP) than Plaque Psoriasis and the General Population: A US-Based Claims Analysis.

Background: Limited literature exists on the mortality burden of generalized pustular psoriasis (GPP) in the US.

Objective: To compare all-cause mortality among patients with GPP with matched populations of patients with plaque psoriasis (PsO) and the general population in the US.

Methods: An observational study was conducted using US claims data collected between January 1, 2016 and December 31, 2019.

Deucravacitinib in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis: Improvements in Joint Pain and the Impact of Musculoskeletal Symptoms.

Introduction: For patients with psoriasis, psoriatic arthritis can be a painful comorbid condition that is often undiagnosed. It is therefore essential that more research is done to understand which treatments for psoriasis relieve both dermatologic and joint symptoms. This analysis aimed to compare the effects of deucravacitinib vs.

Outcomes of PASI and PASI components in two phase 3 trials of deucravacitinib in patients with moderate to severe plaque psoriasis.

Deucravacitinib was significantly more effective than placebo in the 52-week, phase 3 POETYK PSO-1 and PSO-2 trials. This study further evaluated deucravacitinib efficacy versus placebo in these trials based on Psoriasis Area and Severity Index (PASI) outcomes. Patients with moderate to severe plaque psoriasis received placebo or deucravacitinib 6 mg once daily.

From the Masterclasses in Dermatology 2024 Meeting: Updates in Psoriasis Treatments.

Psoriasis (PsO) is an immune-mediated, chronic inflammatory skin disease that significantly impairs quality of life. Its treatment landscape is rapidly evolving, providing better disease control. Here, we highlight updates in biologics, obtaining coverage for biologics under Medicare, the PsO-to-psoriatic arthritis (PsA) transition, and orally administered drugs, as presented at the 2024 Masterclass in Dermatology in Puerto Rico.

Effect of spesolimab on sustained disease control in patients with generalized pustular psoriasis: Post hoc analysis of the EFFISAYIL 2 study.

Background: Generalized pustular psoriasis (GPP) is a chronic inflammatory disease with an unpredictable disease course. Long-term treatment goals include sustained resolution of skin symptoms, prevention of new flares, and improvement in quality of life (QoL).

Objective: To compare the effect of the interleukin-36 receptor monoclonal antibody spesolimab 600 mg subcutaneous (SC) loading dose (LD) followed by 300 mg SC every 4 weeks (q4w) versus placebo on skin symptoms and QoL burden in patients with GPP.

Validation of DermSat-7 for Assessing Treatment Satisfaction in Patients With Psoriasis.

Importance: A critical need exists for developing a validated dermatologic-specific treatment satisfaction instrument.

Objective: To evaluate the structural validity, internal consistency, construct validity, and test-retest reliability of the 7-item dermatology-specific treatment satisfaction (DermSat-7) instrument in patients with psoriasis.

Design, Setting, And Participants: This survey study was conducted from July 2020 to April 2023 in dermatology outpatient clinics at the University of Southern California, Brigham and Women's Hospital, and Mount Sinai Union Square and included adults (aged ≥18 years) with psoriasis who were fluent in English.

Effect of Bimekizumab on Patient-Reported Outcomes and Work Productivity in Patients With Psoriatic Arthritis: 1-Year Results From 2 Phase III Studies.

Objective: To assess the longer-term effect of bimekizumab up to 1 year on patient-reported symptoms, health-related quality of life (HRQOL), and work productivity in patients with active PsA who were biologic disease-modifying antirheumatic drug (bDMARD)-naïve or had inadequate response/intolerance to tumor necrosis factor inhibitors (TNFi-IR).

Methods: BE OPTIMAL (ClinicalTrials.gov: NCT03895203; bDMARD-naïve patients) and BE COMPLETE (NCT03896581; TNFi-IR patients) are phase III studies of subcutaneous bimekizumab 160 mg every 4 weeks.

Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular Events.

Introduction: Psoriasis (PsO), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) may confer an increased risk for cardiovascular (CV) disease, including major adverse cerebro-cardiovascular events (MACE), deep vein thrombosis (DVT), and pulmonary embolism (PE). Patients with these conditions are often exposed for extended time periods to biologics, such as ixekizumab (IXE). Therefore, understanding the risk of CV events, especially MACE, in patients with PsO, PsA, and axSpA exposed to IXE is important.

The association between obesity and efficacy of psoriasis therapies: An expert consensus panel.

Background: Psoriasis is a chronic inflammatory skin disease often associated with obesity. Psoriasis therapies may be less effective in patients with obese. The purpose of this expert consensus panel is to evaluate the relationship between obesity and efficacy of psoriasis therapies, thereby optimizing patient care.

International Dermatology Outcome Measures (IDEOM): A Report From the 2023 Annual Meeting.

Background: International Dermatology Outcome Measures (IDEOM) is a non-profit organization whose mission is to improve the availability of evidence-based, consensus-driven outcome measures for dermatological diseases. IDEOM facilitates collaboration between stakeholders from various backgrounds, including researchers, patients, physicians, and industry representatives, to develop objective benchmark metrics that enable better treatment and management of dermatologic conditions.

Summary: The 2023 IDEOM Annual Meeting was held June 23-24, 2023.